Farther Finance Advisors LLC Purchases 101 Shares of IQVIA Holdings Inc. $IQV

Farther Finance Advisors LLC raised its stake in IQVIA Holdings Inc. (NYSE:IQV) by 34.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 398 shares of the medical research company’s stock after acquiring an additional 101 shares during the period. Farther Finance Advisors LLC’s holdings in IQVIA were worth $63,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of IQV. Clal Insurance Enterprises Holdings Ltd grew its position in IQVIA by 436.7% in the first quarter. Clal Insurance Enterprises Holdings Ltd now owns 161 shares of the medical research company’s stock valued at $28,000 after acquiring an additional 131 shares during the period. Golden State Wealth Management LLC grew its position in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new stake in IQVIA in the first quarter valued at $33,000. Larson Financial Group LLC grew its position in IQVIA by 109.9% in the first quarter. Larson Financial Group LLC now owns 275 shares of the medical research company’s stock valued at $48,000 after acquiring an additional 144 shares during the period. Finally, Atticus Wealth Management LLC bought a new stake in IQVIA in the second quarter valued at $52,000. 89.62% of the stock is currently owned by institutional investors.

Insider Activity

In other IQVIA news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total value of $105,149.97. Following the transaction, the insider owned 2,910 shares of the company’s stock, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider directly owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

IQVIA Trading Up 1.2%

Shares of IQV opened at $206.84 on Monday. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $237.34. The firm has a market capitalization of $35.16 billion, a PE ratio of 29.93, a price-to-earnings-growth ratio of 2.27 and a beta of 1.32. The stock’s fifty day simple moving average is $187.90 and its 200-day simple moving average is $167.44.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business had revenue of $4.02 billion for the quarter, compared to analyst estimates of $3.96 billion. During the same quarter in the prior year, the firm posted $2.64 earnings per share. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Wall Street Analysts Forecast Growth

IQV has been the topic of a number of analyst reports. Barclays upped their price target on IQVIA from $185.00 to $200.00 and gave the company an “equal weight” rating in a research report on Thursday. Robert W. Baird boosted their price objective on IQVIA from $159.00 to $196.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 23rd. Cowen reissued a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. UBS Group boosted their price objective on IQVIA from $185.00 to $225.00 and gave the stock a “buy” rating in a research note on Wednesday, July 23rd. Finally, Mizuho boosted their price objective on IQVIA from $190.00 to $225.00 and gave the stock an “outperform” rating in a research note on Friday, July 25th. Eighteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $230.32.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.